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http:WHAT THIS PAPER ADDS
The problem of the treatment of carotid stenosis in patients with contralateral carotid occlusion has not yet
been resolved. The data in the literature are not clear in this regard and there is no unanimous agreement on
the best technique to be used, speciﬁcally stenting or endarterectomy. Therefore, we have reviewed our own
results on an extensive number of patients and analyzed the available literature using a meta-analysis.Objective/background: The inﬂuence of contralateral carotid occlusion (CCO) on the outcome of carotid
endarterectomy (CEA) and stenting (CAS) is debated. This study aims to evaluate CEA and CAS results in patients
with CCO.
Methods: All carotid revascularizations from 2005 to 2011 were analyzed, focusing on the role of CCO on 30-day
cerebral events and death (CED). A meta-analysis was performed to evaluate the results of the literature by
random effect.
Results: Of the 1,218 carotid revascularizations performed in our institution, 706 (57.9%) were CEA and 512
(42.1%) were CAS. CED occurred in 3.6% of the CEAs and 8.2% of the CASs (p ¼ .001). CCO was present in 37
(5.2%) CEAs and 38 (7.4%) CASs. In CEA, CCO patients had a higher CED compared with the non-CCO patients
(16.2% vs. 2.9%, p ¼ .001), as conﬁrmed by multiple regression analysis (OR [odds ratio]: 5.1[1.7e14.5]). In CAS,
CED was not signiﬁcantly different in the CCO and non-CCO patients (2.6% vs. 8.7%, p ¼ 0.23). The comparative
analysis of the CCO patients showed a higher CED in CEA compared with that in CAS (16.2% vs. 2.6%, p ¼ 0.04).
Meta-analysis of 33 papers (27 on CEA and 6 on CAS) revealed that CCO was associated with a higher CED in CEA,
but not in CAS (OR: 1.82 [1.57e2.11]; OR: 1.22 [0.60e2.49], respectively).
Conclusion: CCO can be considered as a risk factor for CED in CEA, but not in CAS. CAS appears to be associated
with lower CED than CEA in CCO patients.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Stroke, TiaINTRODUCTION
Carotid artery stenosis is associated with contralateral ca-
rotid artery occlusion (CCO) in approximately 10% of pa-
tients.1e3 In those patients, cerebral perfusion is maintained
by the contralateral stenosed carotid artery and by the
vertebro-basilar circulation, through the circle of Willis. The
revascularization procedures available for carotid sten-
osisdendarterectomy (CEA) and stenting (CAS)din patients
with CCO can temporarily decrease cerebral ﬂow and could
inﬂuence the outcome of the procedure.4e6 Several series of
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//dx.doi.org/10.1016/j.ejvs.2013.03.021events,7e10 although some others do not.11e14 In CAS, CCO
does not appear to inﬂuence the outcome.15,16 Few papers
are available in the literature that directly compare the re-
sults of CEA and CAS in patients with CCO.
The aim of the present work was to evaluate the inﬂu-
ence of CCO on the perioperative outcome in a series of
patients submitted to CEA and CAS, and to analyze the
experience reported in the literature through a meta-
analysis.METHODS
Study design and setting
Consecutive patients who were submitted to carotid
revascularization from January 2005 to December 2011 in a
single centre were prospectively entered into a dedicated
database and retrospectively reviewed. All patients gave
their informed consent for the procedure.
G. Faggioli et al. 11The main aim of the study was to evaluate and compare
the inﬂuence of CCO on the primary outcome (any post-
operative cerebral event and death) in CEA and CAS. We
also evaluated the inﬂuence of the preoperative symptoms
on the results of CEA and CAS in patients with and without
CCO.
Variables and surgical methods
Carotid revascularizations were performed according to the
European Society of Vascular and Endovascular Surgery
guidelines.17 The clinical characteristics, technical aspects,
preoperative neurologic symptoms, and perioperative (30-
day) outcome were considered. The clinical characteristics
speciﬁcally included the following: age; sex; hypertension
(presence of a systolic blood pressure of >140 mmHg and/
or a diastolic blood pressure of >90 mmHg, or speciﬁc
therapy); dyslipidemia (total cholesterol>200 mg/dL or low
density lipoprotein >120 mg/dL, or speciﬁc therapy); dia-
betes mellitus (prediagnosed in therapy with oral hypogly-
cemic drugs or with insulin); current smoking; coronary
artery disease (CAD, deﬁned as a history of angina pectoris,
myocardial infarction, or coronary revascularization);
chronic obstructive pulmonary disease (deﬁned as chronic
bronchitis or emphysema); and chronic renal failure (CRF, a
glomerular ﬁltration rate of <60 mL/min). The preoperative
neurologic symptoms were evaluated by independent in-
hospital neurologists and were deﬁned as transient
ischemic events or strokes occurring in the last 24 weeks in
the hemisphere ipsilateral to the target carotid stenosis.
Carotid revascularization was performed for symptomatic
carotid artery bifurcation stenosis of >60% (according to
the North American Symptomatic Carotid Endarterectomy
Trial [NASCET] criteria18) and asymptomatic carotid artery
stenosis of >70% (according to the NASCET criteria), as
suggested by the European Society of Vascular and Endo-
vascular Surgery guidelines.17
The CEA procedures were performed with routine
shunting and patching.
In patients with appropriate clinical or anatomic char-
acteristics, the CAS procedure was performed as described
previously.19 Brieﬂy, the patients were taken to the
angiographic suite after providing appropriate informed
consent. A cardiologic evaluation was performed, and the
patients were medicated with 100 mg aspirin and 75 mg
clopidogrel for 3 days before the procedure. All procedures
were performed under local anesthesia and systemic
heparinization, and with an 8F groin introducer. Common
carotid cannulation was achieved using 40 Boston Sci-
entiﬁc (Natick, MA, USA) or Medtronic (Minneapolis, MN,
USA) HS I and II catheters over a Terumo (Leuven,
Belgium) stiff guide wire. When cannulation could not be
achieved by these means, several alternative techniques
were used (i.e., buddy wire or coaxial). Brachial or carotid
access was not attempted in any case. Routine cerebral
protection was accomplished using FilterWire EZ (Boston
Scientiﬁc) and closed-cell stenting (Wallstent, Boston Sci-
entiﬁc) was used. “Technical success” was deﬁned as
treatment resulting in less than 30% residual stenosis. Theneurologic outcomes were evaluated both at the end of
the procedure and over the following 24 h by a neurologist
using the National Institutes of Health stroke scale and the
modiﬁed Rankin scale.
As perioperative (30-day) outcomes we considered ce-
rebral events (considered to be postoperative stroke that
was clinically evaluated by the neurologist and with a new
acute ischemic lesion identiﬁed by a cerebral computed
tomography scan, or a transient cerebral ischemic event
and transient focal neurologic deﬁcit with complete reso-
lution within 24 h, and no new ischemic lesion on the ce-
rebral computed tomography scan) and death. For a clear
analysis of the results, the occurrence of any cerebral event
or death was considered cumulatively to be a primary
adverse outcome; secondary adverse outcomes were eval-
uated separately for each category of complications (tran-
sient cerebral events, stroke, and death).
Statistical methods
Continuous variables were expressed as mean  SD and
frequencies by percentages. Analyses of the differences
between the two groups were performed using Fisher’s
exact test or chi-square test for categorical variables and
unpaired Student t test, or the ManneWhitney U test for
continuous variables. The multivariable analyses were per-
formed using the regression model including the signiﬁcant
(p < .05) or closing signiﬁcant (p < .20) variables from the
previous univariable analysis in the models. A value of
p < .05 (2-tailed) was considered to be signiﬁcant. The
statistical tests were performed using SPSS 13.0 for Win-
dows (SPSS, Chicago, IL, USA).
Meta-analysis methods
Research protocol, eligibility criteria, and study selection.
An English-language literature review was performed
through PubMed, Scopus, and Science Direct for any study
reporting the outcome in terms of stroke and death after
carotid revascularization by CEA or CAS, including the re-
sults from patients with CCO, until March 2012.
Two investigators (RP and RM) performed the research.
The mesh terminology used for search purposes included
‘contralateral’ [All Fields] AND ‘carotid’ [All Fields] AND
‘occlusion’ [All Fields] AND (‘endarterectomy’ [All Fields]
OR ‘stenting’ [All Fields]). The investigators independently
reviewed the titles and abstracts of all citations to identify
potentially relevant studies and to exclude duplicates. They
reviewed the full text of the corresponding publications to
assess if the studies met the inclusion criteria. The refer-
ences from the articles obtained were also analyzed. The
exclusion criteria were as follows: case reports; studies
with no extractable data on stroke and death; and multiple
publications on overlapping populations. Unpublished data
or data reported only in abstracts were not included. The
ﬁnal inclusion of the studies was based on agreement be-
tween the reviewers. We resolved disagreements by dis-
cussion and consultation with the other authors if
necessary. The articles were categorized to perform three
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ence of CCO on the postoperative stroke and death rates
after the CEA and CAS procedures; the third aimed to
analyze data from articles comparing CEA and CAS out-
comes in patients with CCO. Prospective, retrospective,
and case-control studies were included in the ﬁrst two
meta-analyses; the third meta-analysis include only ran-
domized controlled trials. We applied the guidelines for the
Meta-analysis of Observational Studies in Epidemiology.20
Data extraction and quality assessment. Three in-
vestigators (RP, RM, and GF) used the standardized extrac-
tion database (Microsoft Excel) to extract information on
outcome (number of patients and 30-day event rates for
death and stroke) with odds ratios (ORs). We assessed study
quality by evaluating the indication for the carotid revas-
cularization procedures, the cerebral protection device used
in CAS, the clinical evaluation of complications, and the
follow-up.
Subgroup evaluations. A number of subgroups were also
analyzed. Primarily, symptomatic and asymptomatic pa-
tients were compared. Next, to identify those studies with a
higher statistical power, the sample size population was
evaluated: considering the presence of CCO in 10% of pa-
tients submitted to carotid revascularization, an a error of
5% and a b error of 20%, the sample required identifying a
difference in the outcome of 3% (from 2% to 5%) was
approximately 300 and 2,800 in procedures with CCO and
without CCO, respectively.21 A further subgroup analysis
was performed according to shunting during the CEA pro-
cedures: studies were stratiﬁed into “no shunt” if shunting
was never used; “selective shunt” if shunting was per-
formed depending on clinical, anatomical, or technical
criteria (electroencephalogram [EEG] modiﬁcation, clinical
modiﬁcation during loco-regional anesthesia, stump pres-
sure evaluation, somatosensory-evoked potential, cerebral
angiographic evaluation, transcranial Doppler sonography
or near-infrared spectroscopy evaluation); and “routine
shunting” if shunting was performed whenever technically
possible.
Study bias evaluation. The bias evaluation (performed by
RP) focused on the indication for carotid revascularization,
the technical characteristics, the evaluation of the out-
comes, and the follow-up. The inter-study bias evaluation
was performed by funnel plot symmetry evaluation.
Statistical analysis was performed using RevMan 5.2
(Copenhagen, Denmark) and Meta-analyst 3.13 (Boston,
MA, USA) software. The pooled stroke and death risk was
expressed as an OR with a 95% conﬁdence interval (CI).
Heterogeneity among the studies was estimated by the
chi-square test and Cochran Q score, reported as I2 and
representing the percent value of heterogeneity. Because
of the heterogeneity of the observational studies, we
assessed a priori by a random effect model. The test for
overall effect was a Z test and the statistical signiﬁcance
level was set to p < .05. The data were graphed as a forest
plot.RESULTS
CEA vs. CAS in the entire population
In a 7-year period a total of 1,218 carotid revascularizations
were performed: 706 (57.9%) CEA and 512 (42.1%) CAS. The
CEA and CAS groups were similar in regard to male gender,
preoperative neurologic symptoms, hypertension, and dia-
betes, (64.6% vs. 65.3, p ¼ .80; 27.7% vs. 28.7%, p ¼ .60;
91.0% vs. 88.8%, p ¼ .20; 29.3% vs. 27.0%, p ¼ .37,
respectively). The patients in the CAS group had a higher
incidence of coronary artery disease and chronic renal
failure compared with those in the CEA group (37.7% vs.
25.7%, p ¼ .01 and 17.9% vs. 11.2%, p ¼ .01, respectively)
and were signiﬁcantly older (75.6  6.7 vs. 70.1  8.6,
p ¼ .01). The patients in the CEA group had a higher inci-
dence of dyslipidemia and smoking compared with those in
the CAS group (63.4% vs. 37.1%, p ¼ .001 and 20.9% vs.
9.4%, p ¼ .01, respectively). The CCO prevalence was similar
in the two groups: 37 (5.2%) in CEA and 38 (7.4%) in CAS,
p ¼ .10.
The following postoperative complications occurred in
the CEA and CAS groups, respectively: 8 (1.1%) vs. 28 (5.4%)
transient cerebral events (p ¼ .001); 13 (2.0%) vs. 15 (2.8%)
(p ¼ 0.37) strokes; 21 (3.0%) vs. 43 (8.3%) overall cerebral
events (p ¼ .001); 4 (0.6%) vs. 0 (0.0%) deaths (p ¼ 0.42);
and 25 (3.2%) vs. 43 (8.3) overall complications (any cere-
bral event or death) (p ¼ .001). In the multivariable analysis
using the binary regression model, the CEA was indepen-
dently associated with a lower incidence of the primary
outcome (any cerebral event and death) with an OR of 0.35
and a 95% CI of 0.20e0.63. This analysis was based on the
preoperative neurologic symptoms, sex, age > 80 years,
CAD, CRF, dyslipidemia, and smoking.CEA outcomes in presence of CCO
During the study period, 706 CEA were performed, with 37
(5.2%) in CCO patients. The clinical and surgical technical
characteristics were similar in the CCO and other patients
submitted to CEA (Table 1). The incidence of postoperative
events was signiﬁcantly higher in patients with CCO
compared with patients without CCO: 5 (13.5%) vs. 19
(2.9%) primary adverse outcomes (any cerebral event and
death), p ¼ .001. The CCO patients had a higher incidence
of secondary adverse outcomes compared with the no-CCO
patients: 2 (5.4%) vs. 6 (0.9%), p ¼ 0.01 transient cerebral
events; 3 (8.1%) vs. 10 (1.7%), p ¼ .007 strokes; 5 (13.5%)
vs. 16 (2.4), p ¼ .001 all cerebral events; and 1 (2.7%) vs. 3
(0.5%), p ¼ .07 deaths.
As shown in Table 2, among the 189 symptomatic pa-
tients submitted to CEA, 13 (6.3%) had CCO. A signiﬁcant
difference was observed with respect to the primary
adverse outcomes between the CCO and non-CCO patients:
3 (25%) vs. 7 (4%), p ¼ .02. No signiﬁcant differences were
observed with respect to the secondary adverse outcomes:
strokes (there were no transient cerebral events in symp-
tomatic patients) and death rate were 2 (15.2%) vs. 7
(4.0%), p ¼ .12 and 1 (7.7%) vs. 0 (0%), p ¼ .06,
Table 1. Clinical characteristics, medical therapy, and clinical outcomes of patients submitted to carotid endarterectomy (CEA) and carotid
stenting (CAS) according to carotid artery occlusion (CCO).
CEA CEA with CCO p CAS CAS with CCO p
n (%) n (%) n (%) n (%)
Clinical characteristics
Agea 70.4  8.4 65  10.8 .001 75.6  6.7 76.6  7.1 .37
Male sex 427 (64.5) 25 (67.6) .70 301 (63.9) 28 (73.6) .09
Preoperative neurologic symptoms 176 (26.8) 13 (35.1) .26 135 (28.8) 12 (30.8) .79
Hypertension 602 (91.1) 33 (91.7) .90 413 (88.2) 36 (97.3) .09
Dyslipidemia 415 (62.8) 26 (74.3) .16 171(36.5) 19 (51.4) .07
Diabetes 192 (29.0) 11 (31.4) .76 133 (28.5) 9 (23.6) .80
Smoke 140 (21.2) 5 (14.3) .32 47 (10.0) 3 (10.7) 1.0
Coronary artery disease 171 (25.9) 7 (20.0) .43 178 (38.0) 16 (43.2) .53
Chronic obstructive pulmonary disease 92 (13.9) 3 (8.6) .36 100 (21.4) 10 (27.8) .37
Chronic renal failure 76 (11.5) 2 (5.9) .31 83 (17.8) 9 (24.3) .32
Medical therapy
Antiplatelet 592 (83.1) 34 (91.8) .90 512 (100) 38 (100) 1.0
Statins 520 (73.0) 30 (81.0) .18 420 (82.0) 31 (81.5) .90
Primary outcome
Any cerebral event or death 19 (2.9) 6 (16.2) .001 42 (8.7) 1 (2.6) .23
Secondary outcome
Transient cerebral event 6 (0.9) 2 (5.4) .01 27 (5.7) 1 (2.6) .42
Stroke 10 (1.7) 3 (8.1) .007 15 (3.2) 0 (0.0) .26
Any cerebral event 16 (2.4) 5 (13.5) .001 42 (8.7) 1 (2.6) .23
Death 3 (0.5) 1 (2.7) .07 0 (0.0) 0 (0.0) 1.0
Note. Categorical variables are expressed as percentage and compared using the chi- square test; p < .05 was considered to be signiﬁcant.
a Continuous variables are expressed as means  SD and compared using the Student t test; p < .05 was considered to be signiﬁcant.
Table 2. Clinical outcome of patients submitted to carotid
endarterectomy (CEA) and carotid stenting (CAS) according to
carotid artery occlusion (CCO) and the symptomatic status.
CEA CEA
with
CCO
p CAS CAS
with
CCO
p
n (%) n (%) n (%) n (%)
Symptomatic patients
Primary outcome
Any cerebral
event or death
7 (4.0) 3 (25.0) .02 16 (11.9) 0 (0.0) .61
Secondary outcome
Transient
cerebral event
0 (0.0) 0 (0.0) e 7 (5.2) 0 (0.0) 1.0
Stroke 7 (4.0) 2 (15.2) .12 9 (6.6) 0 (0.0) 1.0
Any cerebral
event
7 (4.0) 2 (15.2) .12 16 (11.9) 0 (0.0) .61
Death 0 (0.0) 1 (7.6) .07 0 (0.0) 0 (0.0) 1.0
Asymptomatic patients
Primary outcome
Any cerebral
event or death
12 (2.3) 3 (12.5) .01 26 (7.8) 1 (3.7) .70
Secondary outcome
Transient
cerebral event
6 (1.2) 2 (8.3) .05 20 (6.0) 1 (3.7) 1.0
Stroke 3 (0.6) 1 (4.2) .17 6 (1.8) 0 (0.0) 1.0
Any cerebral
event
9 (1.8) 3 (12.5) .004 26 (7.8) 1 (3.7) .70
Death 3 (0.6) 0 (0.0) 1.0 0 (0.0) 0 (0.0) 1.0
Note. Categorical variables are expressed as percentages and
compared using the chi-square test; p < .05 was considered
signiﬁcant.
G. Faggioli et al. 13respectively. There were 517 asymptomatic patients sub-
mitted to CEA, with 15 (3.0%) having CCO. As shown in
Table 2, the asymptomatic patients with CCO had a higher
primary adverse outcome rate compared with asymptom-
atic patients with no CCO (3 [12.5%] vs. 9 [1.9%], p ¼ .01; 3
[12.5%] vs. 12 [2.5], p ¼ .02, respectively). For the sec-
ondary adverse outcomes, no signiﬁcant difference was
observed between the CCO and non-CCO patients.
In the multivariable analysis using the binary regression
model, the presence of CCO was independently associated
with a higher overall complication rate (any cerebral event
and death) with an OR of 5.1 and a 95% CI of 1.7e14.5. This
analysis was based on the preoperative neurologic symp-
toms, sex, statin therapy, dyslipidemia, and age >80 years.
CAS outcomes in the presence of CCO
During the study period, 512 CASs were performed, with 38
(7.4%) in CCO patients. Clinical characteristics and endo-
vascular technique were similar in patients with CCO and
with no CCO (Table 1). The primary adverse outcome rate
was not signiﬁcantly different among the two groups: 1
(2.6%) in the CCO patients vs. 42 (8.8%) in the non-CCO
patients, p ¼ .18. As shown in Table 1, the secondary
adverse outcome rate was not signiﬁcantly different be-
tween the patients with CCO and with no CCO.
As shown in Table 2, the primary adverse outcomes were
not signiﬁcantly different in the symptomatic patients with
and without CCO: 0 (0%) vs. 16 (11.9%), p ¼ .61.
Similarly, the primary adverse outcomes were not
signiﬁcantly different in the asymptomatic patients with
and without CCO: 1 (3.7%) vs. 26 (7.6%), p ¼ .70.
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model the presence of CCO was not associated with a
higher primary outcome incidence (any cerebral event and
death): OR of 0.3 and 95% CI of 0.04e2.31; the analysis was
based on preoperative neurologic symptoms, sex, and age
>80 years.
CEA vs. CAS in CCO patients
CCO was present in 37 patients submitted to CEA and 38 pa-
tients submitted to CAS. The clinical characteristics were
similar in both groups of patients except for the higher inci-
denceof CADandCRF, and the older ageof patients submitted
toCAS (Table 3).Theprimary adverse outcomes in the CEAand
the CAS CCO patients were 6 (16.2%) and 1 (2.7%), p ¼ .04,
respectively. No signiﬁcant differences were found in the
secondary adverse outcomes in these two groups (Table 3).
Meta-analysis results
Fig. 1 shows the study selection process. We found 27 pa-
pers on CEA and 6 on CAS with data available for the meta-
analysis of patients with CCO and non-CCO, and no papers
with stroke and death data for patients with CCO submitted
to CEA or CAS.Table 3. Clinical characteristics, medical therapy, and clinical
outcomes of carotid artery occlusion (CCO) patients submitted to
carotid endarterectomy (CEA) vs. carotid stenting (CAS).
CEA with CCO
(n ¼ 37)
CAS with CCO
(n ¼ 38)
p
n (%) n (%)
Clinical characteristics
Agea 65  10.8 76.6  7.1 .01
Male sex 25 (67.6) 28 (73.6) .61
Preoperative neurologic
symptoms
13 (35.1) 12 (30.8) .80
Hypertension 33 (91.7) 36 (97.3) .43
Dyslipidemia 26 (74.3) 19 (51.4) .10
Diabetes 11 (31.4) 9 (23.6) .79
Smoke 5 (14.3) 3 (10.7) .48
Coronary artery disease 7 (20.0) 16 (43.2) .04
Chronic obstructive
pulmonary disease
3 (8.6) 10 (27.8) .07
Chronic renal failure 2 (5.9) 9 (24.3) .05
Medical therapy
Antiplatelet 34 (91.8) 38 (100) .11
Statins 30 (81.0) 31 (81.5) 1.0
Primary outcome
Any cerebral event
or death
6 (16.2) 1 (2.6) .04
Secondary outcomes
Transient cerebral event 2 (5.4) 1 (2.6) .10
Stroke 3 (8.1) 0 (0.0) .08
Any cerebral event 5 (13.5) 1 (2.6) .07
Death 1 (2.7) 0 (0.0) .31
Note. Categorical variables are expressed as percentages and
compared using the chi-square test; p < .05 was considered to
be signiﬁcant.
a Continuous variables are expressed as means  SD and
compared using the Student t test; p < .05 was considered
signiﬁcant.CEA in patients with CCO. Twenty-seven studies met the
inclusion criteria. Seventeen were retrospective single-
centre studies,1,7,11e14,22e32 four were retrospective multi-
centre studies,8e10,33 one was a case-control study,34 one
was a prospective single-centre study,35 and four were
randomized controlled trials.2,3,36,37 Fig. 2 shows the forest
plot of all studies; the overall OR was 1.82 (95% CI: 1.57e
2.11), with a low level of heterogeneity (I2 ¼ 0%) and a high
level of signiﬁcance (Z ¼ 7.83, p < .00001).
Two studies1,3 met the inclusion criteria for the subgroup
meta-analysis of CEA in symptomatic patients with CCO
compared with no CCO. As shown in the forest plot in Fig. 3,
the CCO had an OR of 2.43 (95% CI: 1.07e5.50) and a
moderate level of heterogeneity I2 ¼ 43% (Z ¼ 2.13,
p ¼ .03).
Four studies met the inclusion criteria for the subgroup
meta-analysis of CEA in asymptomatic patients with CCO
compared with those without CCO, as shown in the forest
plot in Fig. 3, the CCO had an OR of 1.83 (95% CI: 1.25e
2.68) and a low level of heterogeneity I2 ¼ 0% (Z ¼ 2.13,
p ¼ .002).
In the meta-analysis subgroup of studies with a higher
statistical power, ﬁve studies met the inclusion criteria
(Fig. 3):8e10,31,33 the OR was 1.75 (95% CI: 1.44e2.12), and
there was a low level of heterogeneity I2 ¼ 0% (Z ¼ 5.71,
p < .00001).
In the evaluation of shunt use during CEA 18 studies met
the inclusion criteria. In two studies, the CEA was performed
with no shunt use (Fig. 4),10,24 but, in the study of Frawley
et al.,24 thiopental sodium was used in cases of EEG modiﬁ-
cation. Both studies showed a trend of an increased risk of
stroke and death in patients with CCO compared with pa-
tients with no CCO. This trend was conﬁrmed by the meta-
analysis: the OR was 2.61 (95% CI 0.91e7.46) and a low
level of heterogeneity I2¼ 7% (Z¼ 1.79, p< .07) was found.
The results of CEA performed with selective shunting were
reported in 12 studies: three with EEG evaluation,12,25,34 one
with evaluation by preoperative cerebral angiogram,35 one
with stump pressure,27 one with somatosensory-evoked po-
tential,28 two with a clinical evaluation during loco-regional
anesthesia,1,26 and one with a decision made at the sur-
geon’s discretion.7 Three studies reported multiple types of
evaluation: two used EEG or clinical evaluation during loco-
regional anesthesia,30,31 and one used EEG or clinical evalu-
ation during loco-regional anesthesia or stump pressure
evaluation.10 The presence of CCO was also a risk factor for
stroke and death in themeta-analysis of studies reporting the
use of selective shunting with an OR of 1.83 (95% CI: 1.34e
2.52) and a low level of heterogeneity I2 ¼ 0% (Z ¼ 3.77,
p < .0002) (Fig. 4).We considered the different methods for
the evaluation of whether to use shunting to be a possible
bias across the studies.
Six studies10,11,13,29,32,37 reported the results from CEA in
CCO patients compared with no-CCO patients with routine
shunt use; CCO was a risk factor of stroke and death in the
studies reporting the use of routine shunting with an OR of
2.14 (95% CI: 1.28e3.32) and a low level of heterogeneity
I2 ¼ 0% (Z ¼ 3.40, p < .0007) (Fig. 4).
Figure 1. Flow chart for selection of the studies. Note. CCO ¼ contralateral carotid occlusion; CEA ¼ carotid endarterectomy;
CAD ¼ carotid stenting.
G. Faggioli et al. 15The inter-study bias evaluation of patients who have
undergone CEA with and with CCO was performed by the
funnel plot analysis, which showed a good level of
symmetry.
CAS in patients with CCO. Six studies met the inclusion
criteria.15,16,38e41 All of these studies were retrospective
studies, with one being a national (German) registry38 and
ﬁve being single-centre experiences.15,16,31e41 All studies
included symptomatic and asymptomatic patients, but did
not divide the patients into those with or without CCO. No
studies were appropriate for the subgroup meta-analysis
(either for symptomatic status or the sample size). Fig. 5
shows the forest plot of all studies: the overall OR was
1.22 (95% CI: 0.60e2.49); there was a low level of het-
erogeneity: I2 ¼ 23% (Z ¼ 0.55, p < .58).
The inter-study bias evaluation of patients who under-
went CAS with and with without CCO was performed by
funnel plot (Fig. 6) analysis, which showed a low level of
symmetry.
CEA vs. CAS in patients with CCO. The International Ca-
rotid Stenting Study (ICSS)42 included the data and
outcome of patients with CCO submitted to CEA and CAS,
but presented this information as the composite outcome
of stroke, death, and myocardial infarction. The ICSS
included 49 patients with CCO in the CAS group and 37 inthe CEA group, and all patients were symptomatic. There
were two (4.3%) events in the CAS group with CCO and
one (3.7%) in the CEA group with CCO, with no signiﬁcant
difference between the two groups (OR: 1.51, 95% CI:
0.14e16.61).
DISCUSSION
The present observational, nonrandomized study on 1,218
carotid revascularizations showed that CEA is generally
associated with a minor perioperative incidence of any ce-
rebral event and death compared with CAS (3.2% vs. 8.3%,
p ¼ .001). These results are similar to those of the most
recent, wider, randomized controlled trials (Carotid Revas-
cularization Endarterectomy or Stent Trial (CREST)43 and
ICSS42), which had stroke/death rates of 2.3% vs. 4.4%
(p ¼ .005) and 4.2% vs. 8.0% (p ¼ .001), respectively.
CCO is an uncommon condition in patients submitted to
contralateral carotid revascularization: 6.1% in our series,
which is consistent with 5e10% reported in other
studies.1e3 In our series, CCO was an independent risk
factor of adverse events (for any cerebral event and death)
in CEA, with an OR of 5.1 (95% CI: 1.7e14.5), but not in
CAS. The comparison of the two carotid revascularization
techniques in patients with CCO showed a higher incidence
of adverse events in patients submitted to CEA compared
with those submitted to CAS (16.2% vs. 2.6%, p ¼ .04).
Figure 2. Forest plot showing the pooled odds ratio (OR) for 30-day stroke and death after carotid endarterectomy (CEA) in patients with
contralateral carotid occlusion (CCO) and with no CCO. Note. M-H ¼ Mantel-Haenszel; CI ¼ conﬁdence interval.
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confounding elements owing to the observational non-
randomized design of the study. Patients submitted to CAS
were more frequently older, with coronary artery disease
and chronic renal failure. Despite these clinical differences
CAS showed better results compared with CEA in CCO
patients.
The inﬂuence of CCO in the CEA patients is reported
differently in the literature. CCO is reported to be a risk
factor for adverse CEA outcomes by subgroup analysis of
different randomized controlled trials in both symptom-
atic1,3 and asymptomatic patients,1,2,8,36 with an increasing
risk of postoperative cerebral events of up to 14%. NASCET
showed that the 30-day risk of stroke/death was signiﬁ-
cantly higher in symptomatic patients with CCO (14.3%)
compared with patients with a patent contralateral internal
carotid artery (approximately 5%). Despite the higher
operative risk, CEA still lead to a highly signiﬁcant reduction
of the 2-year risk of ipsilateral stroke compared with
medically-treated patients (absolute risk reduction: 47.3%).
In asymptomatic patients, the issue is more controversial.3
In post hoc Asymptomatic Carotid Atherosclerosis Study
data analysis Becker et al.36 concluded that “endarterec-
tomy in asymptomatic subjects with contralateral occlusion
provides no long-term beneﬁt (and may be harmful) in
preventing stroke and death” because of the increasedperioperative complications in the surgical arm. In contrast,
many other authors do not consider CCO as being a sig-
niﬁcant risk factor for CEA.11e14 In patients submitted to
CAS, CCO is not considered to be a risk factor of adverse
outcome by any researchers because these patients have
similar results compared with patients with patency of
contralateral internal carotid artery.15,16,38e41 However, the
deﬁnitive role of CAS remains controversial, particularly in
asymptomatic patients. Even if most complications in our
series were transient cerebral events with a prompt, un-
eventful recovery, the cumulative adverse event rate was
12% in symptomatic patients and 8% in asymptomatic pa-
tients, with postoperative stroke rates of 6.6% and 1.8%,
respectively. Therefore, our data conﬁrm the contemporary
recommendations of the major vascular societies favoring
CEA rather than CAS in asymptomatic patients17 given the
higher risk of the latter technique. However, because the
presence of CCO appears to increase the risk of complica-
tions, particularly in the surgical arm, CCO itself can be
added to other characteristics to be considered in the
choice of the revascularization technique, similarly to other
anatomical factors.
In the present series, the low number of carotid revas-
cularization procedures in CCO patients, the retrospective
design, and the statistical limitation did not allow a com-
parison of the surgical and endovascular techniques.
Figure 3. Forest plot showing the pooled odds ratio (OR) for 30-day stroke and death after carotid endarterectomy (CEA) in patients with
contralateral carotid occlusion (CCO) and with no CCO, according to the preoperative (6 months) presence of neurologic symptoms
(symptomatic patients), the absence of neurologic symptoms (asymptomatic patients), and the sample size of the studies. Note.
M-H ¼ Mantel-Haenszel; CI ¼ conﬁdence interval.
G. Faggioli et al. 17However, our results suggest a better outcome of CAS
compared with CEA in patients with CCO.
In general, randomized clinical trials comparing CEA with
CAS do not speciﬁcally address the inﬂuence of CCO. The
meta-analysis of different trials (ICSS,42 CREST,43 Stent-
Supported Percutaneous Angioplasty of the Carotid Artery
(SPACE)44 and Endarterectomy vs Angioplasty in Patients with
Symptomatic Severe Carotid Stenosis (EVA3S)45) showed that
the presence of CCO or contralateral severe carotid stenosis
was associated with the same outcome of CEA. To better
analyze the issue, we performed ameta-analysis of the papers
reporting the results of CEA and CAS in patients with CCO.The
outcome of themeta-analysis was in accordance with our own
results: in the CEA group CCO is a risk factor for stroke and
death in both symptomatic and asymptomatic patients. This
ﬁnding holds true in the subgroup analysis, particularly in
those papers with a higher statistical power (Fig. 3).
Shunting, either routine or selective, did not inﬂuence
the overall results. Independent from the use of a shunt
during the CEA procedures, CCO remained a predictor of
stroke and death in the meta-analysis. This result could be
explained by greater atherosclerotic involvement of the
cerebral vessels in patients with CCO. Two papers10,24reporting the outcome of CEA performed routinely
without shunting failed to show a difference between pa-
tients with and without CCO, but did show a trend with of
CCO as a risk factor. The reasons for this association are
difﬁcult to explain. In one series, cerebral protection was
obtained through high dosage of thiopental sodium in cases
of EEG modiﬁcation, which may partially explain the re-
sults.24 Additionally, we can consider the different methods
used to evaluate the indication for shunting (EEG, loco-
regional anesthesia, stump pressure, somatosensory
evoked potential, cerebral angiography, transcranial
Doppler sonography, or near-infrared spectroscopy) as a
possible selective bias of the meta-analysis.
In patients submitted to CAS, CCO does not inﬂuence the
outcome of the procedure (Fig. 5).We only found one paper
reporting a comparative analysis of CEA and CAS in patients
with CCO. In that trial, which reported the results of 86 pa-
tients with CCO submitted to CEA (37 patients) or CAS (49
patients), both techniques led to a similar outcome.42 Simi-
larly, unpublished data from the Society for Vascular Surgery
Vascular Registry, recently presented at the 2012 Society for
Vascular Surgery meeting, conﬁrm the present results,
reporting a higher incidence of stroke, death, and myocardial
Figure 4. Forest plot showing the pooled odds ratio (OR) for 30-day stroke and death after carotid endarterectomy (CEA) in patients with
contralateral carotid occlusion (CCO) and with no CCO, according to the use of shunting during CEA. Note. M-H ¼ Mantel-Haenszel;
CI ¼ conﬁdence interval.
18 European Journal of Vascular and Endovascular Surgery Volume 46 Issue 1 July/2013infarction in 666 patients with CCO compared with 16,646
patients with no CCO (4.20% vs.1.76%, p < .0001), but the
higher risk was not identiﬁed in patients submitted to CAS
(2.75% in CCO vs. 3.16% with no CCO) (J.J Ricotta, G.R.
Upchurch, G.S. Landis, C.T. Kenwood, F.S. Siami, J. J. Ricotta,
R. A. White. The inﬂuence of contralateral occlusion on re-
sults of carotid interventions from the Society for VascularFigure 5. Forest plot showing the pooled odds ratio (OR) for 30-day st
contralateral carotid occlusion (CCO) and with no CCO. Note. M-H ¼Surgery (SVS) Vascular Registry. Abstract presented at
Vascular Annual Meeting, Washington, DC, 2012).
In conclusion, CCO appears to be a risk factor in CEA, but
not in CAS. The superiority of one revascularization tech-
nique over the other, however, must be demonstrated in
this setting, and further studies comparing CAS and CEA in
patients with CCO should therefore be performed.roke and death after carotid artery stenting (CAS) in patients with
Mantel-Haenszel; CI ¼ conﬁdence interval.
Figure 6. Funnel plots of studies on carotid endarterectomy (CEA) and stenting (CAS) in patients with and without carotid artery occlusion.
Note. OR ¼ odds ratio.
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